Tags

Type your tag names separated by a space and hit enter

Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections.
Ann Pharmacother 2004; 38(9):1377-82AP

Abstract

BACKGROUND

The rate of methicillin-resistant Staphylococcus aureus (MRSA) has increased significantly over the last decade. Previous cohort studies of patients with MRSA bacteremia have reported higher mortality rates, increased morbidity, longer hospital length of stay (LOS), and higher costs compared with patients with methicillin-susceptible S. aureus (MSSA) bacteremia. The clinical and economic impact of MRSA involving other sites of infection has not been well characterized.

OBJECTIVE

To determine the clinical and economic implications of MRSA compared with MSSA infections across a variety of infection sites and severity of illnesses.

METHODS

A retrospective, case-control analysis comparing differences in clinical and economic outcomes of patients with MRSA and MSSA infections was conducted at an academic medical center. Case patients with MRSA infection were matched (1:1 ratio) to control patients with MSSA infection according to age, site of infection, and type of care.

RESULTS

Thirty-six matched pairs of patients with S. aureus infection were identified. Baseline characteristics of patients with MSSA and MRSA infection were similar. Patients with MRSA infections had a trend toward longer hospital LOS (15.5 vs 11 days; p = 0.05) and longer antibiotic-related LOS (10 vs 7 days; p = 0.003). Median hospital cost associated with treatment of patients with MRSA infections was higher compared with patients with MSSA infections ($16,575 vs $12,862; p = 0.11); however, this difference was not statistically significant. Treatment failure was common in patients with MRSA infection. Among patients with MSSA infections, treatment failure was associated with vancomycin use.

CONCLUSIONS

Patients with MRSA infections had worse clinical and economic outcomes compared with patients with MSSA infections.

Authors+Show Affiliations

Adult Critical Care, Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721-0207, USA. kopp@pharmacy.arizona.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

15266044

Citation

Kopp, Brian J., et al. "Clinical and Economic Analysis of Methicillin-susceptible and -resistant Staphylococcus Aureus Infections." The Annals of Pharmacotherapy, vol. 38, no. 9, 2004, pp. 1377-82.
Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother. 2004;38(9):1377-82.
Kopp, B. J., Nix, D. E., & Armstrong, E. P. (2004). Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. The Annals of Pharmacotherapy, 38(9), pp. 1377-82.
Kopp BJ, Nix DE, Armstrong EP. Clinical and Economic Analysis of Methicillin-susceptible and -resistant Staphylococcus Aureus Infections. Ann Pharmacother. 2004;38(9):1377-82. PubMed PMID: 15266044.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. AU - Kopp,Brian J, AU - Nix,David E, AU - Armstrong,Edward P, Y1 - 2004/07/20/ PY - 2004/7/22/pubmed PY - 2004/10/27/medline PY - 2004/7/22/entrez SP - 1377 EP - 82 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 38 IS - 9 N2 - BACKGROUND: The rate of methicillin-resistant Staphylococcus aureus (MRSA) has increased significantly over the last decade. Previous cohort studies of patients with MRSA bacteremia have reported higher mortality rates, increased morbidity, longer hospital length of stay (LOS), and higher costs compared with patients with methicillin-susceptible S. aureus (MSSA) bacteremia. The clinical and economic impact of MRSA involving other sites of infection has not been well characterized. OBJECTIVE: To determine the clinical and economic implications of MRSA compared with MSSA infections across a variety of infection sites and severity of illnesses. METHODS: A retrospective, case-control analysis comparing differences in clinical and economic outcomes of patients with MRSA and MSSA infections was conducted at an academic medical center. Case patients with MRSA infection were matched (1:1 ratio) to control patients with MSSA infection according to age, site of infection, and type of care. RESULTS: Thirty-six matched pairs of patients with S. aureus infection were identified. Baseline characteristics of patients with MSSA and MRSA infection were similar. Patients with MRSA infections had a trend toward longer hospital LOS (15.5 vs 11 days; p = 0.05) and longer antibiotic-related LOS (10 vs 7 days; p = 0.003). Median hospital cost associated with treatment of patients with MRSA infections was higher compared with patients with MSSA infections ($16,575 vs $12,862; p = 0.11); however, this difference was not statistically significant. Treatment failure was common in patients with MRSA infection. Among patients with MSSA infections, treatment failure was associated with vancomycin use. CONCLUSIONS: Patients with MRSA infections had worse clinical and economic outcomes compared with patients with MSSA infections. SN - 1060-0280 UR - https://www.unboundmedicine.com/medline/citation/15266044/Clinical_and_economic_analysis_of_methicillin_susceptible_and__resistant_Staphylococcus_aureus_infections_ L2 - http://journals.sagepub.com/doi/full/10.1345/aph.1E028?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -